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ABSTRACT

MITOCHONDRIAL TARGETING OF THE PRO-APOPTOTIC PROTEIN BAX

Stephanie Erin Brock
July 08, 2009

Here, I address the function of the carboxy-terminal hydrophobic helix of
the pro-apoptotic protein Bax. There has been considerable controversy as to
whether this sequence is required for the targeting and insertion of Bax into the
mitochondrial outer membrane. The Bax carboxy-terminal tail is tucked into a
hydrophobic pocket within the closed/inactive conformation of Bax.

Apoptotic

stimulation results in an opening of the Bax conformation, exposing a
mitochondrial-targeting signal and
mitochondrial outer membrane.

subsequent insertion of Bax into the

Here, I confirm that the Bax tail alone can

specifically target and anchor a cytosolic passenger protein to the mitochondria.
Surprisingly, however, I find that the carboxy-terminal tail is not responsible for
the specific targeting of Bax to the mitochondria rather than other cellular
membranes. Specifically, replacing the Bax tail with an ER-targeting tail-anchor
had no effect on Bax mitochondrial targeting, in the context of full-length Bax.
This contrasts to the targeting function of tail-anchor signals in other tailanchored proteins. In addition, I demonstrated that the Bax tail has a negative

IV

regulatory effect on Sax activation. Mutations that disrupt the interaction of the
Sax tail with the hydrophobic pocket resulted in an open/active conformation of
Sax and constitutive mitochondrial targeting.

Deletion of the Sax tail also

resulted in an open/active conformation of Sax, however the anchor-deleted form
of Sax was not associated with mitochondria. This indicates a requirement of the
Sax tail for mitochondrial translocation. Sy introducing charged residues into the
tail sequence to block insertion of the sequence into the hydrophobic bilayer, I
show that insertion of the Sax tail is required for Sax mitochondrial targeting. My
data support a model whereby the Sax tail must be released from its hydrophobic
pocket to initiate the change into an open/active conformation.

The tail then

functions as an anchor to stabilize Sax at the mitochondrion after the initial
addressing step.
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CHAPTER I
INTRODUCTION

Apoptosis

Apoptosis is an important process whereby cells can induce their own
demise. It is carried out by specific pathways in the cell that are tightly-regulated.
This process of cell suicide was first described in 1842 by Carl Vogt, but wasn't
cOined "apoptosis" until 1972 by John Kerr

Kerr JF, 1972.

Programmed cell death is

essential for the specific cell turnover in developmental processes as well as in
tissue homeostasis. It is also important in the elimination of damaged or infected
cells

Strasser

A,

2000.

Cells

undergoing

apoptosis

display very

distinct

characteristics. These include cell shrinkage, chromatin condensation, DNA
fragmentation, membrane blebbing, and exposure of phosphatidyl serine on the
outer leaflet of the plasma membrane. Apoptotic cell death is stimulated by two
distinct pathways (Figure 1). One pathway is triggered by death receptors at the
cell surface.

The other pathway is initiated by cellular stress signals.

Both

pathways ultimately result in activation of proteases known as caspases. The
death receptor pathway involves activation of death receptors including TNF, Fas
and TRAIL receptors

Ashkenazi A, 1998.

Stimulation by the respective death ligands

triggers a signaling cascade within the cell. This leads to activation of caspases
by triggering a specific proteolytic cleavage of the inactive procaspases to
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Figure 1. Two main pathways to apoptosis. Intracellular stress signals are
mediated through the Bcl2 family, whereas the death-receptor pathway is
activated by signals from other cells. Activity of caspase-9 and caspase-3 is
restrained by inhibitor of apoptosis proteins (lAPs), but the lAPs can be
countermanded by Diablo/Smac and OmilHtrA2, which are released from
damaged mitochondria. Apaf1, apoptotic protease-activating factor 1; cyt c,
cytochrome c; FADD, Fas associated death-domain; FasL, Fas ligand; TNF-a,
tumournecrosis

factor-a;

TRAIL,

tumour-necrosis-factor-related

inducing ligand.
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apoptosis-

1
produce active enzymes.
death.

These caspases then act as the executors of cell

Caspase substrates include apoptotic proteins, inhibitors of apoptotic

proteins, DNA repair enzymes, structural proteins, and negative regulators of
endonucleases

Strasser A, 2000.

The stress pathway is initiated by intrinsic stress

signals (eg. DNA damage, oxidative stress, ER stress) or by outside signals (eg.
growth factor withdrawal, irradiation, cytotoxins). Apoptosis is dependent on the
mitochondria in this pathway

Jin Z, 2005.

The BcI-2 family of proteins deciphers and

transfers these death signals to the mitochondria, inducing the release of
apoptogenic factors (eg. Cytochrome c) from the mitochondria into the cytosol
Green DR, 1998.

complex.

Cytochrome c then interacts with Apaf-1 to form the apoptosome
The apoptosome cleaves pro-caspase-9 to activate caspase-9,

initiating the caspase activation cascade.
The apoptotic machinery must be kept in check, so that aberrant cell
death does not occur

Strasser A, 2000.

Inhibitors of apoptosis are found throughout

both the death receptor and stress-signal pathways. Examples include the lAPs
(inhibitors of apoptosis) that bind and inhibit caspases, and the anti-apoptotic
members of the bcl-2 family (bcl-2, bcl-xL) that inhibit the pro-apoptotic bcl-2
members (bax, bak). The Bcl-2 family will be described in greater detail in the
next section. De-regulation of the apoptotic process is involved in a variety of
disease states. When apoptosis is running un-checked, abnormal amounts of
cell death occur. This can lead to neurodegeneration or cardiac disease. On the
other hand, when apoptosis is not activated when cued, infected or damaged

4
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cells can accumulate. This can lead to states of tumorigenesis or autoimmune
disease.

The Bcl-2 family of proteins

The BcI-2 protein was identified in 1984 where it was found to be
aberrantly overexpressed in human B-cell lymphoma due to a chromosome
translocation

Tsujimoto Y, 1984.

Further studies showed that it was functioning in the

inhibition of apoptosis in these cells. Following the identification of BcI-2, various
proteins containing homologous domains were discovered

Adams JM, 1998.

These

are shown in Figure 2. These proteins contain conserved domains referred to as
bcl-2 homology domains (BH1, BH2, BH3 or BH4). Most members of this family
contain multiple homology domains, whereas some of these proteins contain only
the BH3 domain. The BcI-2 protein family plays a central role in the stress-signal
pathway of apoptosis

Cory s, 2002.

Some of the BcI-2 proteins induce apoptosis,

while others inhibit apoptosis. The anti-apoptotic members all contain at least 3
of the BH domains, and include proteins such as BcI-2, Bcl-xL, and Mcl-1. The
pro-apoptotic members include multi-domain proteins (ie. Bax and Bak), as well
as BH3-only proteins (ie. Bid and Bim). Various members of the BcI-2 family can
interact with themselves, as well as with other BcI-2 family members.
interactions are mediated via the BH3 domain

Adams JM, 1998.

These

These intricate

interactions determine whether or not the cell will undergo apoptosis (Figure 3).
The anti-apoptotic Bcl-2 proteins can heterodimerize with the pro-apoptotic BcI-2
proteins, thereby inhibiting apoptotic activation. The BH3-only proteins serve as
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Figure 2. The Bcl-2 family. Three subfamilies are indicated: The BcI-2 cohort

promotes cell survival, whereas the Bax and BH3 cohorts facilitate apoptosis.
BH1 to BH4 are conserved sequence motifs. The Bax subfamily resembles the
Bcl-2 subfamily but lacks a functional BH4 domain. Except for the BH3 domain,
the BH3 subfamily is unrelated to BcI-2. All proteins compared are mammalian
(usually human), except for NR-13 (chicken), CED-9, and EGL-1 (C. elegans) ,
and the viral proteins BHRF1, LMW5-HL, ORF16, KS BcI-2, and E1B- 19K.
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1
activators of the pro-apoptotic Bcl-2 proteins by direct interaction or indirectly by
interacting with and inhibiting the anti-apoptotic Bcl-2 proteins.
Proteins within this family are localized primarily at the mitochondria, but
also to some extent at the endoplasmic reticulum (Figure 4). While some Bcl-2family proteins are constitutively localized to their respective membranes, some
require conformational changes or posttranslational modifications to translocate
to

membranes

Schinzel

A,

2004.

Posttranslational

modifications

include

phosphorylation/dephosphorylation, proteolytic cleavage, release from inhibiting
proteins, or dissociation from intracellular structures.

Role of Sax in apoptosis

Bax was discovered by Dr. Stanley Korsmeyer's group in the early 1990's
Oltvai ZN, 1993.

In Korsmeyer's study, Bax was identified due to its interaction with

Bcl-2. Although Bax is similar in structure to BcI-2, Bax was found to work in
opposition to BcI-2 and promote apoptosis.

Bax and its closely-related Bcl-2

family member, Bak, playa redundant role in triggering apoptosis. The presence
of one or the other is essential for the intrinsic apoptotic pathway
MC, 2001; Zong WX, 2001.

Cheng EH, 2001; Wei

Mutation or deletion of Bax results in a small impairment of

the apoptotic-inducing ability of cells, whereas disruption of Bak function does not
exhibit any effects on apoptosis.

However, inactivation of both Bax and Sak

conveys resistance to various apoptotic stress stimuli in a variety of cell lines.
Exogenous expression of Sax can rescue this effect.

9
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Figure 4.

Localization and posttranslational modifications of Bcl-2

proteins. Posttranslational modification is required for the translocation of certain
multidomain and BH3-only Bcl-2 family members, whilst some proteins are
directly targeted to and inserted into the mitochondrial outer membrane (MOM)
and/or the ER membrane (Bak, BcI-xL and BcI-2). In response to an apoptotic
stimulus, BH3-only proteins (yellow) translocate to interact with multidomain Bcl2 family members on the MOM. Bim and Bmf dissociate from cytoskeletal

,

structures, Bad from 14-3-3 and Bid is proteolytically cleaved. Bax and BcI-w
undergo a conformational change, which allows them to translocate and/or insert
into the MOM.
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In the normal state of cells, Sax is found as a soluble monomer within the
cytosol. This conformation of Sax consists of a bundle of 9 a-helices (Figure 5)
Suzuki M, 2000.

The C-terminal tail (a-helix9) of Sax is tucked within a hydrophobic

pocket. Within this pocket, the Sax tail functions to hide two important domains,
the SH3 domain and a-helices 5 and 6. The SH3 domain is essential for Sax
activity due to its requirement for oligomerization.
considered to be the "pore-forming domain" of Sax

Helices 5 and 6 are

Annis MG, 2005.

induction, Sax trans locates to a mitochondrial-bound form
Goping IS, 1998; Hsu YT, 1998; Nechushtan A, 1999; Hou Q, 2005

Upon apoptotic

Hsu YT, 1997; Wolter KG, 1997;

Translocation is due to a

conformational change of Sax, resulting in a more open structure and exposure
of a mitochondrial-targeting signal.

This open conformation of Sax can be

detected using a conformation-specific antibody (termed 6a7) that binds to an Nterminal epitope. This epitope is normally hidden in the closed conformation of
Sax

Hsu YT, 1998; Hsu YT, 1997; Yethon JA, 2003.

The mitochondrial-bound form of Sax

consists of insertion of the putative "pore-forming domain" a-helices 5 and 6, and
the C-terminal tail a-helix9

Annis MG, 2005.

This was determined by chemically

labeling residues within the potential transmembrane sequences of a-helices 5,
6, and 9. A membrane-impermeant modifying agent was then used to probe for
the chemical labels. Insertion within the bilayer protected against modification of
the chemical labels. At the mitochondrial outer membrane (MOM), Sax homooligomerizes and stimulates the release of apoptotic factors such as cytochrome
c from the mitochondria
JurgensmeierJM, 1998.

Antonsson S, 2000; Antonsson S, 2001; Annis MG, 2005; Sharpe JC, 2004;

Cytochrome c then interacts with Apaf-1 in the cytosol, initiating

12
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Figure 5. Structure of Bax. A ribbon representation of an averaged minimized
NMR structure for the closed conformation of Bax. Helices are distinguished by

different colors. Residues 816- A35, A54-D71, M74-A81, R89-M99, G108-C126,
P130 E146, L149-D154, W158-Y164, W170-W188 make up helices a1, a2, a3,
a4, a5, a6, a7, a8, a9, respectively. a-helix9 is designated by lime green.
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the formation of the oligomeric apoptosome complex. The apoptosome complex
promotes activation of caspases in the cell, resulting in cell death.
Bax has been widely studied, yet the details of its activation remain
unclear. Addition of an apoptotic cytosolic extract can induce Bax translocation
to mitochondria in vitro. This supports the notion that soluble cytosolic factors
can activate Bax

Goping IS, 1998; Nomura M, 1999.

Many apoptotic stimuli that induce Bax

activation have been identified, yet the mechanisms that lead to this activation
remain to be elucidated. One generally accepted model is that the BH3-only BcI2 family members, such as Bid and Bim, interact directly with Bax, leading to Bax
activation

Kuwana T, 2005; Eskes R, 2000; Desagher S, 1999; Marani M, 2002; Roucou

x,

2002.

However,

other activation mechanisms, and control of Bax activation, appear to operate as
well

Ruffolo SC, 2000; Wu Y, 2007.

Proteins including Ku70, humanin, and 14-3-3 have

been identified to interact with Bax and inhibit Bax translocation and activation
Sawada M, 2003; Guo S, 2003; Nomura M, 2003.

Anti-apoptotic Bcl-2 family proteins such as

Bcl-2 and Bcl-xL also act to prevent Bax conformational change, translocation,
oligomerization and activity

Jurgensmeier JM, 1998; Finucane OM, 1999; Murphy KM, 2000; Yi X, 2003;

Antonsson S, 2001; Dlugosz PJ, 2006; Billen LP, 2008.

Therefore, activation of Bax could be partly

due to disruption of these inhibitory interactions. Known activators and inhibitors
of Bax are displayed in Figure 6. Bax inserted at the membrane can also act to
recruit cytosolic Bax to the mitochondria. This autoactivation leads to a positive
feedback loop after initial Bax targeting

Billen LP, 2008.

Bax action at the MOM is also incompletely understood.

One model

describes a Bax interaction with pre-existing MOM channels that is responsible

15
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for the release of apoptotic factors. Specifically, Sax has been shown to interact
with the voltage-dependent anion channel (VDAC or porin) and the adenine
nucleotide translocator (ANT).

These two channels comprise the permeability

transition pore (PTP) of the mitochondria
2002; Belzacq AS, 2003.

Marzo I, 1998; Narita M, 1998; Brenner C, 2000; Capano M,

According to this model, Sax cooperates with these channels

to allow for passage of apoptotic components through the pores. However, the
detection of these Sax interactions with the PTP have been challenged
1998; Finucane DM, 1999; Antonsson B, 2001; Mikhailov V, 2001.

Eskes R,

Specific blocking of the PTP does

not inhibit Sax-induced release of cytochrome c in vitro

Eskes R, 1998.

These results

support a second model in which Sax oligomerization alone leads to direct pore
formation allowing for release of these factors. During apoptosis, Sax is found in
an oligomeric state at the MOM. This oligomerization is mediated by the SH3
domain of Sax

Antonsson B, 2001; Zha H, 1996; Wang K, 1998.

In vitro studies have shown that

Sax oligomers can form pores in artificial membranes
Schlesinger PH, 1997; Antonsson B, 2000; Saito M, 2000.

Adams JM, 1998; Antonsson B, 1997;

Sax oligomers can also mediate the

release of cytochrome c from isolated mitochondria, whereas monomeric Sax
cannot.

In

addition,

a glycoprotein,

clusterin,

specifically

oligomerization, subsequently inhibiting Sax-induced apoptosis

blocks

Sax

Zhang

2005

H,

These data indicate that Sax oligomerization is essential for the release of
apoptotic factors from the mitochondria.
For the most part, Sax specifically translocates to the mitochondria.
However, a small portion of Sax can also localize to the endoplasmic reticulum
(ER) to mediate apoptosis (Figure 7). ER stress agents can induce translocation
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Figure 7. Sax and Sak localized to the ER can initiate apoptosis. In addition
to their mitochondrial localization and activity, Sax and Sak also reside at the ER.
Upon ER stress treatment, Sax and Sak can initiate apoptosis from the ER.
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and oligomerization of Bax at the ER. This subsequently induces caspase 12
cleavage and apoptosis

Zong WX, 2003; Adams JM, 1998.

Studies have shown that Bax

can regulate Ca2+ storage of the ER. This can then increase the Ca2+ uptake into
the mitochondria, thereby triggering apoptosis
Oakes SA, 2005.

Nutt LK, 2002; Nutt LK, 2002; Scorrano L, 2003;

A direct interaction of Bax with the ER transmembrane protein,

IRE1a, has also been detected. IRE1a mediates the unfolded protein response
(UPR) of the ER

Hetz C, 2006.

Therefore, it seems that depending on the upstream

apoptotic stimulus, Bax can translocate to the mitochondria or the ER to induce
apoptosis (Figure 8)

Scorrano L, 2003.

Bax in disease states

Because Bax is a key determinant in cell death, Bax inactivation or overactivation has been implicated in a variety of disease states (Figure 9).
Impairment of Bax-induced apoptosis can lead to autoimmune disease or
oncogenesis. Bax conditional deletion results in an increased number of B cells
and results in severe autoimmune disease in adult mice

Takeuchi 0,2005.

The role of

Bax in tumorigenesis has been studied to a much greater extent. Analysis of Bax
expression and Bax function in a variety of different cancer cells indicates that
Bax possesses tumor-suppressor function.

Bax expression was shown to be

downregulated in hepatocellular carcinomas as well as in breast cancer
2000; Bargou RC, 1995

amino-acid

Beerheide W,

Frameshift mutations, missense mutations, and/or single

substitutions

have

been

detected

in

colorectal

cancers,

gastrointestinal cancers, hematopoietic malignancies, stomach cancers, and
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Figure 8.

Schematic representation of BAXIBAK control points of

apoptosis at level of ER Ca 2+ or mitochondria and categories of stimuli that
demonstrate a requirement for each or display dual use of the pathways.
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endometrial cancers

Rampino N, 1997; Gil J, 1999; Yamamoto H, 1997; Meijerink JP, 1998; Ouyang H, 1998.

Cells deficient in Sax expression, including epithelial cancer cells and colon
carcinoma cells, displayed resistance to multiple apoptotic-inducing stimuli and
anti-cancer agents

Zhang L, 2000; LeBlanc H, 2002; Theodorakis P, 2002.

Additionally, Sax

deficiency in mice displayed increased tumor growth and decreased apoptotic
ability

Yin C, 1997.

These results designate Sax as a possible therapeutic target in

oncogenesis. Initial studies have produced promising results of the therapeutic
potential of Sax.

Exogenous overexpression of Sax increased apoptotic

induction sensitivity in breast and pancreatic cancer
ZW, 2002

Sakakura C, 1996; Wagener C, 1996; Xu

Furthermore, overexpression of Sax using adenoviral delivery or

tetracycline-dependent expression resulted in increased apoptosis and tumor
regression in prostate cancer, lung cancer, and breast cancer mouse models

Li X,

2001; Kagawa S, 2000; Lowe SL, 2001

Aberrant

amplification

of

Sax-induced

apoptosis

can

cause

neurodegenerative or cardiac disease states. Increased levels of Sax have been
found in a variety of neurological disorders including Alzheimer's disease,
Parkinson's disease, and Huntington's disease.

Studies have shown that

Alzheimer's disease is associated with overexpressed levels of Sax, resulting in
increased neurodegeneration

Paradis E, 1996; Su JH, 1997; Tortosa A, 1998.

In a transgenic

mouse model of Huntington's disease, Sax was overexpressed in affected areas
of the brain and correlated with increased levels of apoptosis compared to
controls

Teles AV, 2008.

Abnormal overexpression of Sax is also seen in brain tissue

of deceased Parkinson's disease patients compared to tissue from control
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r
patients

Vila M, 2001.

It should be noted that it is difficult to distinguish cause and

effect of Sax overexpression and nuerodegeneration in these studies. However,
deletion of Sax increases resistance to neural cell death in a Parkinson's disease
model, suggesting that Sax could be a therapeutic target in neurodegenerative
disorders
disease

Vila M, 2001; Perier C, 2007.

Sax is also a potential therapeutic target for heart
Activation and translocation of Sax is

Haunstetter A, 1998; Haunstetter A, 2000.

detected during cardiac ischemia/reperfusion
Gupta S, 2005

Lundberg KC, 2004; Hou Q, 2005; Capano M, 2006;

Furthermore, absence of Sax results in increased resistance to

ischemialreperfusion in mouse hearts

Hochhauser E, 2003.

In Sax homozygous

knockout mice (-/-) , significant protective effects with ischemia/reperfusion
treatment, as well as resistance to myocardial infarction, were detected
compared to Sax homozygous wild-type mice (+/+)

Hochhauser E, 2007; Hochhauser E, 2003.

Bax mitochondrial targeting and the C-terminal tail

The principle action of Sax is at the mitochondrial membrane.

The

mechanisms that target Sax to the mitochondria remain a matter of controversy.
In particular, there is disagreement about the role of a hydrophobic alpha
helix (a-helix9) at the carboxy-terminus of Bax in Bax targeting and
activation.

The Sax tail is tucked in a hydrophobic pocket within the

inactive/closed conformation of Sax (Figure 10)
2004

Suzuki M, 2000; Cartron PF, 2005; Arokum H,

Upon Sax activation, a conformational change results in release of the tail

from the pocket.

This exposes the previously hidden SH3 domain and

transmembrane a-helices 5 and 6. This conformational change also results in
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FIGURE 10.

Suzuki M, 2000
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Figure 10. The Orientation of the C-terminal Helix. A close-up view of the Sax
C-terminal helix and the hydrophobic pocket is shown. The side chains of the
residues in the C terminal helix are represented by balls and sticks. Magenta
balls represent oxygen atom in threonines and serine. A surface representation
of the pocket is colored red, purple, and yellow to represent negative, positive,
and hydrophobic residues, respectively.
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exposure of a mitochondrial-targeting signal. In one model, upon release from
the hydrophobic groove, the Bax tail serves as the mitochondrial-targeting signal.
This is similar to the function of the C-terminal hydrophobic tail-anchors of Bcl-2,
BcI-xL, and other so-called tail-anchored proteins that will be described in the
next section

Nguyen M, 1993; Kaufmann T, 2003; Borgese N, 2003.

In support of this model, the

Bax C-terminal tail alone is sufficient to target a passenger protein to the
mitochondria

Goping IS, 1998; Schinzel A, 2004.

This model is also corroborated with tail

mutation and deletion studies in full-length Bax Schinzel A, 2004; Wolter KG,
1999.

1997; Nechushtan A,

These studies indicate that the Bax tail can regulate Bax targeting and is

required for Bax mitochondrial localization. Mutation of a single residue (8184)
within the Sax tail has significant effects on Bax translocation

Nechushtan A, 1999.

Deletion of this residue or SUbstitution of this serine with a valine results in
constitutive targeting of Bax to the mitochondria, On the contrary, substitution
with a charged amino acid (lysine, glutamic acid, aspartic acid) inhibits
translocation of Bax.
detected

Phosphorylation at this serine residue has also been

Gardai SJ, 2004; Xin M, 2005.

This phosphorylation is believed to be an

important physiological regulator of Bax targeting.

Specifically, Akt-mediated

phosphorylation at 8184 inhibits Bax translocation and Bax-mediated apoptosis.
Mutation of this serine to a non-phoshorylatable residue abrogates this inhibition.
These findings indicate that the Bax tail alone can regulate Bax targeting.
Complete deletion of the tail (BaxLlC) inhibits mitochondrial localization and
abrogates apoptotic activity of Bax

Schinzel A, 2004; Wolter KG, 1997.

Upon addition of an

apoptotic stimulus, the apoptotic-inducing ability of BaxLlC is comparable to that
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of vector alone.

These results imply that the Bax tail is essential for Bax

targeting and function.
This model has been challenged by reports that the C-terminal tail of Bax
is dispensible for targeting to the mitochondria and subsequent Bax function
In addition, contradictory findings show

Cartron PF, 2003; Cartron PF, 2005; Tremblais K, 1999.

that the Bax tail alone cannot target a passenger protein to the mitochondria
Cartron PF. 2003

This supports an alternative model in which a mitochondrial-

targeting signal is present in Bax outside of the C-terminal tail domain. There
have been reports suggesting a potential mitochondrial-targeting signal within ahelix1 in the N-terminal portion of Bax

Cartron PF, 2003; Cartron PF. 2005; Bellot G, 2007.

This

N-terminal targeting signal can localize a cytosolic passenger protein to the
mitochondria.

This domain was also shown to interact with the well-

characterized mitochondrial import receptor Tom22 and the import channel
Tom40 Bellot G, 2007. Deletion of a-helix1 was shown to abrogate Bax mitochondrial
targeting Cartron

PF. 2003.

In addition, an a-helix1 peptide could compete for binding

of Bax to mitochondria in vitro.

Tail-anchored proteins

Tail-anchored proteins consist of an N-terminal cytosolic globular domain
that is tethered to an intracellular membrane by a C-terminal hydrophobic
transmembrane domain , or tail-anchor
Borgese N. 2003.

Wattenberg BW, 2001; Borgese N, 2003; Habib SJ, 2003;

There are a variety of proteins considered to be tail-anchored

proteins that have been identified and characterized (Table 1). A bioinformatic
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TABLE 1.

Tai~anchored protein

Function

Located

1. Localisation proteins
Vamp. synaptobrevin family,
svntaxin family
Vamp-1B
Sec61 (:I, SeC61"(

SNAREs, mediating events of vesicle
targeting and fusion
Unknown
Protein translocation across endoplasmic
reticulum
Ramp-4
Co-translational protein giycosylation,
ribosome-binding
Sec12
Sarlp binding
SRPR~
Docking receptor for signal recognition
particle
Tom5, Tom6, Tom7, Tom22 Binding translocation of mitOChondrial
precursor proteins
OMP25
Binding of inositol 5'-phosphatase
Fisl.Mdv2. Mdal
Dynamin recruitment protein
Karl
Cdc31 binding and binding to spindle pole
body

Organelles and vesicles of endomembrane
system (endoplasmic reticulum)
Mitochondrial outer membrane
Endoplasmic reticulum
Endoplasmic reticulum
Endoplasmic reticulum
Endoplasmic reticulum
Mitochondrial outer membrane
Mitochondrial outer membrane
Mitochondrial outer membrane
Outer nuclear envelope (endoplasmic
reticuluml

2. EnzYmes and metabolic cofecton
Dolicolphosphate man nose
synthase
Cytochrome b.
OM cytochrome br;
Heme oxygenase
Cytochrome P450
Aldehyde dehydrogenase
Monoamine oxidases
Camitine palmitoyl
transferase I
Pig-A
Ubc6

3. BcI-2 family
Bax
Bok, BcI-x." Bak, Bik, Hrk,
Blk, Bim
BcI-W, MC!-l, Boo
BcI-2, Bc ~XL

Transfer of mannose residues onto lipid
anchor
Electron transfer
Electron transfer
Electron transfer
Electron transfer
Oxidation of small metabolites and drugs
Oxidation of small metabolites and drugs
Transfer of Iong-chain fatty acids

Endoplasmic reticulum
Mitochondrial outer membrane
Endoplasmic reticulum
Endoplasmic reticulum
Endoplasmic reticulum
Mitochondrial outer membrane
Mitochondrial outer membrane

Glycosylphosphoinositide anchc,r synthesis
Conjugation of ubiquitin to substrates

Endoplasmic reticulum Goigi
Endoplasmic reticulum

Pro-apopto!ic function
Pro-apoptotic function

Mitochondrial outer membrane
Unknown

Anti-apoptotic function
Ant~apoPtotic function

Unknown
Mitochondrial outer membrane and
endoplasmic reticulum

Endoplasmic reticulum

Since the biochemical activity of the BcI-2 family of proteins has not yet been defined. there may in fact be only two categories. There
is already much evidence suggesting that the BcI-2 family of proteins acts by localising each other and other proteins to modulate cell
death signals: they might then fall into the first category. Note that the endoplasmic reticulum is continuous with the other
membranes of the secretory system and that tail-anchored proteins, as best illustrated by the SNARES, can be destined for locations
throughout this endomembrane system. The sorting mechanism involved in this redistribution is not known: however, localisation
within the endomembrane system depends on both the transmembrane and the cytoplasmic sequences.
Wattenberg BW, 2001
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study predicts that there are over 400 such proteins encoded in the human
genome

Wattenberg BW, 2007.

The C-terminal transmembrane domain serves two

essential functions in the localization of tail-anchored proteins
Habib SJ, 2003; Borgese N, 2003.

Wattenberg BW, 2001;

First, the transmembrane domain and its flanking

residues contain the sole targeting signal for specific membrane targeting.
The tail alone contains sufficient information to specifically target a
passenger protein to a destination membrane. Second, the C-terminal tail
serves as an anchor to tether the protein to the membrane. Therefore, this
signal-anchor is absolutely required for the correct targeting and insertion
of these proteins. Tail-anchored proteins localize primarily to the endoplasmic
reticulum or the mitochondria, and to a lesser extent at peroxisomal membranes
Borgese N, 2003.

Initial targeting to the ER can be followed by transport to a variety of

other cellular sites by vesicular trafficking.
exclusively at a single membrane.
distributed.

Some proteins are localized

Others, such as BcI-2, are more broadly

The targeting signal within the C-terminal tail that differentiates

between membranes does not consist of specific amino acid sequences.
Instead, distinctive structural characteristics of the tail allow for differential
targeting (Table 2).

These characteristics include hydrophobicity, polarity,

charged flanking-residues, and spacing of residues
S, 1998; Habib SJ, 2003; Borgese N, 2007; Wattenberg BW, 2007.

contain

Borgese N, 2001; Horie C, 2002; Isenmann

ER-targeted tail-anchored proteins

relatively hydrophobic transmembrane sequences.

mitochondrial-targeted

tail-anchored

proteins
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contain

less

Alternatively,
hydrophobic

TABLE 2.

Table 2 List of constructs and summary of results
Construct

Tail-sequence

Mitochondrial
targeting

GFP-MOA Tail

EGFP-LGMDELYKSGSGSKIlGFSTSVTALGFVL Y KKKLLPKS

GFP-LI/\

eGf-P-LGMDEL YKSGSGSKLLLLLLLLLLLLLLLLKKKLLPKS

+++
-(endoplasmic
reticulum)

GFP-G3S5S7T9GI2

EGFP-LGMDELYKSGSGSKLLGLSLSLTLLGLLLLKKKLLPKS

+++

GFP-mS5S7G 12
OFP-mS 7T90 12

eGW-LGMDEL YKSGSGSKLLGLSLSLLLLGLLLLKKKLLPKS
eGI-P-LGMDEL YKSGSGSKLLGLLLSLTLLOLLLLKKKLLPKS

++

GFP-G3S7GJ2

eGI-P-LGMDEL YKSGSGSKLLGLLLSLLLLGLLLLKKKLLPKS

-(endoplasmic
reticulum)

KAKLLPRS

eGf-P-LGMDEL YKSGSGSKLLGLSLSL lLLGLLLLKAKLLPKS
eGf-P-LGMDEL YKSGSGSKLLGLSLSL TLLGLLLLKAAAKA

++

KAAAKA
KAAK

eGI-P-LGMDEL YKSGSGSKLLGLSLSLTLLGLLLLKAAK

++

KAKA

eGI-P-LGMDELYKSGSCiSKLLGLSLSLTLLGLLLLKAKA
eGI-P-LGMDEL Y KSG SOS KLLGLSLSLTLLGLLLLKK

++

KK

+++

++

+/-(endoplasmic
reticulum)

Shown are the names given to constructs (column II the sequence of the sequence of (,-terminus of each
construct and a summary of localizati(ID experiments for each con.~truct. In bold type are positively charged
residues. Underlined is the presumptive transmembrane sequence
Wattenberg BW, 2007
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transmembrane domains due to the presence of polar residues or due to
containing shorter transmembrane segments.

The mitochondrial-targeting tail

anchors also contain positively-charged residues that flank the transmembrane
sequence. Because the C-terminal sequence is the final portion of the protein to
exit the ribosome during translation, targeting to the destination membrane is
post-translational.

Due to the hydrophobic nature of the tail-anchor, the tail is

most likely bound by a cytosolic factor, such as a molecular chaperone, upon
release from the ribosome (Figure 11)

Lan L, 2000; Wattenberg BW, 2001.

In the case of

Sax, the protein itself acts as its own chaperone, whereby the CRterminal
tail folds into a hydrophobic pocket within Sax

Suzuki M, 2000.

It has not yet

been established whether a proteinaceous component directly acts as a receptor
for tail-anchored proteins at the membrane
Wattenberg BW, 2001.

Kim P, 1997; Stefanovic S, 2007; Ahting U, 2005;

Some studies have shown that pre-treating membranes with

proteases abolishes targeting, while others have shown that this pre-treatment
has no effect. In addition, potential membrane receptors have been identified.
The requirement for a protein receptor at the membrane remains a matter of
controversy.
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FIGURE 11.

N

+ \

Wattenberg BW, 2001
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Figure 11. Stages of targeting tail-anchored proteins to mitochondria.
Nascent tail-anchored proteins can fold co-translationally in the cytoplasm and, to
keep the polypeptide soluble in the cytosol, the hydrophobic tail-segments might
interact with factors such as molecular chaperones (green). The identity of the
soluble factor(s) is not known, but they might include general molecular
chaperones such as HSP70, which are involved in the targeting of other protein
precursors to the endoplasmic reticulum and mitochondria. Facilitation of tailanchor insertion into the membrane mayor may not involve the TOM complex.
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Localization of Bax to the mitochondria is an essential step in Baxmediated apoptosis.

However, the mechanisms that facilitate this

translocation are not well-understood. It has generally been accepted that
Bax is a tail-anchored protein.

According to this view the C-terminal

transmembrane domain facilitates targeting and anchoring of Bax to the
mitochondria.

However, contradictory results have made the role of the

Bax tail in mitochondrial targeting a matter of debate.

In light of these

observations, I aim to elucidate the function of the C-terminal tail of Bax in
mitochondrial translocation.
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CHAPTER II
MATERIALS AND METHODS

Cell culture

Mouse embryonic fibroblasts (MEFs) and Hela cells were grown in
Dulbecco's modified Eagle's medium (OM EM) with 10% heat-inactivated fetal
bovine serum (FBS), 20mM HEPES buffer (pH7.4), 2mM glutamine, 100U/mL
penicillin, and 100llg/mL streptomycin.

The MEFs used were generated from

Bax/8ak knockout mouse embryos and were generously provided by Dr. Chi Li
(University of Louisville). Hela cells were purchased through the American Type
Tissue Collection. All cells were incubated at 37°C in 5% CO 2 for culturing.

Construct generation

Baxa in the vector pcDNA3 was a gift from Dr. Richard Youle (National
Institute of Health).

Bax was amplified from this vector using PCR and was

subcloned into p1RES-ne03 using EcoR1 and Not1 restriction enzymes. eGFP
was then cloned into the N-terminal flanking region of Bax using Nhe1 and
EcoR1 restriction enzymes to generate pIRES-eGFP-Baxa.

The carboxy-

terminal tail portion (residues 166-192) of 8ax-WT was amplified from the pIRESeGFP-Bax construct using the following primers: 5' primer 5'- CCC CGG ATC
CGG GAC GCC CAC GT -3' and 3' primer 5'- CCC CTC TAG ATC AGC CCA
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TCT TCT TCC AGA TGG -3'.

The amplified fragment was then cloned into

pcDNA3-eGFP using BamH1 and Xba1 to generate pcDNA3-eGFP-Bax-tail.
The shortened version of the WT-tail construct (residues 169-192) was
generated using the QuikChange site-directed mutagenesis kit (Stratagene) to
delete

residues

166-169

from

pcDNA3-eGFP-tail

(WT).

The

forward

mutagenesis primer used was 5' -GCT GTA CM GTC TGG TTC TGG ATC CAC
GTG GCA GAC CGT GAC C -3'. The carboxy-terminal tail deleted form of Bax
was generated by amplification from pIRES-eGFP-Baxa using the following
primers: 5' primer 5'- GGG GGA ATT CGC CAC CAT GGA CTA CM GGA CGA
CGA CGA CM AGA CGG GTC CGG GGA GCA -3' and 3' primer 5'- CCC CGC
GGC CGC TCA GGG CGT CCC AM GTA G-3'. The amplified product was
then cloned back into pIRES-eGFP-Baxa using EcoR1 and Not1 restriction
enzymes, thereby replacing Baxa.

The resulting construct was pIRES-eGFP-

BaxL1C. Amino acid substitutions for the Bax tail mutants were created using the
QuikChange site-directed

mutagenesis kit (Stratagene)

according to the

manufacturer's protocol. The template and the 5' to 3' primers used for each
mutant are listed in Table 3.

Some mutants required a two-step sequential

mutagenesis. Each mutant was generated as a full-length Bax construct as well
as a GFP-Bax-tail construct.

The amino-terminal deleted forms of Bax were

generated by amplification from pIRES-eGFP-Baxa (wild-type, 3xL, or 6xL) using
the following primers: 5' primer 5'- GGG GGA ATT CGC CAC CAT GGA CTA
CM GGA CGA CGA CGA CM AGG AGG GGA GGC ACC CGA G -3' and 3'
primer 5'- CCC CGC GGC CGC TCA GCC CAT CTT CTT CCA G -3'.
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The

TABLE 3.

Table 3 List of mutagenesis priners
Bax mutant

Template

5'-3' Primer sequence

3xL

Bax WT

1st round: CGCCCACGTGGCAGCTCGTGCTCATCTTTGTGGCGGG
2nd round: GTGCTCACCGCCTCACTCCTCATCTGGMGAAGATGGGC

6xL

Sax 3xL

1st round: GCTCGTGCTCATCTTTGTGGCGCTAGTGCTCACCGCCTC
2nd round: GCTCATCTTTGTGGCGCTAGTGCTCCTCGCCTTGCT

T186K

BaxWT

GTGCTCACCGCCTCACTCMGATCTGGMGAAGATGGGC

G179K

BaxWT

GMGGTGACCATCTTTGTGGCGAMGTGCTCACCGCCTC

S184K

BaxWT

GCGGGAGTGCTCACCGCCAAACTCACCATCTGGAAGMG

S184D

BaxWT

GGCGGGAGTGCTCACCGCCGATCTCACCATCTGGAAGMG

S184E

BaxWT

GGCGGGAGTGCTCACCGCCGAACTCACCATCTGGAAGAAG

V180K,L185K

BaxWT

1st round: GACCATCTTTGTGGCGGGAAAGCTCACCGCCTCACTCACCATC
2nd round: GCGGGAAAGCTCACCGCCTCAAAGACCATCTGGAAGMGATGGGC

Shown are a list of the names given to the Bax tail mutants. The terJ1)late construct used for each of the mutants
is listed as well as the 5' to 3' primer sequences used. Underlined nucleotides indicate mutated sites.
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amplified product was then cloned back into pIRES-eGFP-Baxa using EcoR1
and Not1 restriction enzymes, thereby replacing Baxa. The resulting constructs
were

pIRES-eGFP-Bax~N

(wild-type, 3xL, or 6xL). All constructs were confirmed

by sequencing.

Antibodies

Polyclonal anti-GFP (#A 11122) and polyclonal anti-PARP (214/215)
cleavage site (#44698G) were from Invitrogen. Polyclonal anti-Calnexin (#SPA860) was from Stressgen. Monoclonal anti-Bax (6a7) (#556467) and monoclonal
anti-Cytochrome c (#556433) were from BD Biosciences. Polyclonal anti-LDH-A
(N14) (#sc-27230) and horseradish peroxidase conjugated bovine anti-goat (#sc2350) were from Santa Cruz.

Polyclonal anti-Tom20 was produced by this

laboratory in rabbits using GST-Tom20 as an antigen. Polyclonal anti-cleaved
caspase-3 (Asp175) (#9661) was from Cell Signaling Technology. Horseradish
peroxidase conjugated goat anti-rabbit (#31460) and horseradish peroxidase
conjugated goat anti-mouse (#31430) were from Pierce.

Confocal microscopy

MEF (bax-/bak-) cells were grown on fibronectin-coated, 12mm round
coverslips (Fisherbrand) within the wells of a 24-well plate. Cells were plated at
7 x 104 cells/well for FuGENE transfection and 9 x 104 cells/well for
LipoFectamine transfection.
DNAl2~L

Transfection was done 24h later using 1~g

FuGENE (Roche Diagnostics) or
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0.8~g DNAl2~L

Lipofectamine2000

(Invitrogen) per well, following the protocol of the manufacturer. Indicated cells
were treated with 10J/m2 ultraviolet (UV) light 24h after transfection. 1h after UV
treatment, cells were washed in PBS, fixed in fresh 4% paraformaldehyde for
10min at RT, and permeabilized using PBS/0.1 % Triton X-1 00. Primary antibody
incubation with the indicated antibodies (dilutions: a-Tom20 1:200, a-calnexin
1:1000, a-6a7 1:200) in PBS/0.1% Triton X-100/3% BSA was done for 1h at RT,
followed by a PBS/0.1 % Triton X-100 wash. Secondary incubation was done in
PBS/0.1% Triton X-100/3% BSA for 1h at RT using Red-Alexa 594-goat antirabbit or Red Alexa 594-goat anti-mouse secondary antibody from Molecular
Probes (dilution: 1:500). Cells were then washed with PBS/0.1% Triton X-100
and mounted in fluorescent slide mounting medium from Oako.

Fluorescence

was analyzed under oil immersion using a 60X objective of an Olympus BX51WI
confocal microscope. Images are presented as Z-stacks.

Subcellular fractionation

MEF (bax-/bak-) or Hela cells were plated in 60mm dishes at 1 x 106
cells/dish.

Transfection was done using 8f,lg DNAl20f,lL Lipofectamine2000

according to the manufacturer's protocol.

At 24 hours post-transfection,

designated cells were treated with 8J/m2 UV light. 4h after UV treatment, cells
were harvested by trypsinization and washed with PBS. The pelleted cells were
brought up in 0.5mL MS buffer (210mM mannitol, 70mM sucrose, 5mM Tris,
1mM EDTA, pH 7.5) + complete protease inhibitor (Roche Diagnostics) and
broken with 5 back and forth strokes of a ball-bearing homogenizer as previously
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described

Balch WE, 1985.

The Iysates were cleared of unbroken cells and nuclei

with a 600rpm centrifugation step for 10min in a swing-bucket centrifuge (Sorvall
Legend RT).

Membrane was separated from cytosol by centrifugation of the

cleared lysate for 20min at 100,000rpm in a TlA 100.2 rotor using an ultracentrifuge (Beckman Optimax, Beckman-Coulter).
removed and saved as the cytosolic fraction.

The supernatant was

For the membrane fraction, the

pellet was resuspended in 75/ll MS buffer + complete protease inhibitor and was
subjected to 10 passages through a 26-gauge needle. For alkaline extraction,
the pellet was instead resuspended in 75/ll Na 2 C0 3 (0.1 M, pH 11.5) for 30min at
4°C with gentle agitation. The alkaline treated sample was then centrifuged as
above in a Beckman Optimax ultra-centrifuge. The supernatant was saved as
the alkaline-sensitive fraction. The pellet was resuspended in 75/ll MS buffer +
complete protease inhibitor and was denoted as the alkaline-resistant fraction.
Protein concentration was assessed using Coomassie plus Bradford protein
assay reagent (Pierce). Ten micrograms of each protein fraction was separated
by electrophoresis on poly-acrylamide gels, and then transferred onto PVDF
membranes. After transfer, the membranes were incubated in blocking buffer
(PBS/0.1 % Triton-X 100/5% milk) for 1hr.

After washing in wash buffer

(PBS/0.1 % Triton-X 100), the membranes were incubated with the indicated
primary antibodies in wash buffer for 1h. The membranes were washed in wash
buffer and then incubated in horseradish peroxidase-conjugated secondary
antibody in wash buffer for 1h. After the final washes in wash buffer, ECl-plus
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reagent (Pierce) was added to the membrane and exposure to film was used to
visualize bound antibody.

Immunoprecipitation

MEF (bax-/bak-) cells were plated in T75 flasks at 4 x 106 cells/flask, and
transfected with Lipofectamine2000 using 16f.!g DNAl40f.!L Lipofectamine the
next day. At 24h post-transfection, cells were trypsinized, and two T75 flasks
were pooled for each construct transfected. The cells were washed with PBS
and resuspended in 2mL MS buffer + complete protease inhibitor.

The cells

were lysed by 3 back and forth strokes with a ball-bearing homogenizer. The
Iysates were cleared with a 15min spin at 600rpm in a swinging-bucket
centrifuge.

The resultant supernatant was separated into a membrane and

cytosol fraction as described in the subcellular fractionation section.

The

membrane fraction was resuspended in 0.5mL CHAPS buffer (10mM HEPES,
150mM NaCI, 1% CHAPS, pH 7.4) + complete protease inhibitor and was
passed 10 times through a 26-gauge needle.

The cytosolic fraction was

concentrated to 500f.!L using Amicon Ultra centrifugal filter devices (Millipore),
and NaCI and CHAPS were added to a final concentration of 150mM and 1%,
respectively. One milligram of each membrane or cytosol fraction was incubated
with 2f.!g Bax (6a7) antibody in 500f.!L total volume. Each sample was rotated for
24h at 4 cC.

Forty microliters of protein AlG Plus agarose beads (Santa Cruz)

were then added to each sample and rotated for an additional 2h at 4 cG. The
supernatant was removed and saved as the non-binding fraction.
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The beads

were washed 3 times with CHAPS buffer using centrifugation in an Eppendorf
5415R microcentrifuge at 2500rpm for 1min. The beads were then resuspended
in 50llL 1X SOS Loading Buffer (60mM Tris pH6.8, 2% SOS, 10% glycerol,
0.02% Bromophenol Blue, 10% p-mercaptoethanol) and boiled. The beads were
pelleted and the resulting supernatant, in addition to 20119 of protein of each
corresponding non-binding fraction, was analyzed by Western analysis. Western
analysis was performed as described in the subcellular fractionation section.

Assay for apoptotic markers

Hela cells were plated at 2 x 105 cells/well in a 12-well plate. Transfection
was performed 24h after plating with 1.61lg ONAl41lL Lipofectamine2000. Cells
were harvested by trypsinization at 24h post-transfection. Following the washes,
the cells were resuspended in 751lL extraction buffer (50mM Tris, 150mM NaCI,
0.1% Triton X-100, pH 7.4) + complete protease inhibitor and lysed by passaging
10 times through a 26-gauge needle. The Iysates were cleared by spinning at
13,000rpm for 15min in a Galaxy 140 microcentrifuge (VWR).

Twenty

micrograms of protein were analyzed with Western analysis as described in the
subcellular fractionation section.

Probing of PARP cleavage and caspase-3

cleavage was used as an indicator of apoptosis.
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CHAPTER III
RESULTS

The Bax carboxy-terminal tail is a bona fide mitochondrial-targeting
signal/anchor. Increasing the hydrophobicity of the sequence converts the
Bax signal to an ER targeting signal. The function of a-helix9 within the tail of
Bax has recently been the subject of controversy. To determine the targeting
ability of a-helix9, the tail portion of Bax (residues166-192) was fused to the Cterminus of GFP (Figure 12A). Confocal fluorescence was used to measure the
localization of this construct within mouse embryonic fibroblasts lacking Bax and
Bak (MEF bax-/bak-). In my hands it is quite clear that a-helix9 is a strong and
specific

MOM

targeting

signal

(Figure

12B).

GFP

alone

displays

a

diffuse/cytosolic localization (data not shown).
To address whether the Bax tail serves a specific mitochondrial-targeting
function, I sought to introduce mutations that would alter mitochondrial targeting.
Initially, I explored the effect of these mutations on targeting GFP to the MOM.
Studies from this and other laboratories have established that ER-targeted tailanchored proteins have relatively hydrophobic tails.

In contrast, the tails of

mitochondrially-targeted tail-anchored proteins are less hydrophobic and have
positively charged residues flanking the transmembrane (TM) sequence
2007; Horie C. 2002; Isenmann S. 1998; Wattenberg BW, 2007.
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Borgese N.

Using these general properties as a

guide, I explored the targeting function of the Bax C-terminus. Because the Bax
tail resembles a classic mitochondrial signal, I tested whether increasing the
overall hydrophobicity of the Bax tail could shift targeting from the mitochondria
to the ER.

I specifically mutated polar residues within the Bax tail into

hydrophobic leucines (Figure 12A).

The 3xL tail contains three substituted

leucines, while the 6xL tail is even more hydrophobic with six substituted
leucines. As shown in Figure 12B, the 3xL tail co-localized with the mitochondrial
marker. This indicates that the degree of hydrophobicity is not enough to drive
targeting to the ER. On the other hand, the more hydrophobic 6xL tail targets
GFP to the ER, as seen by the overlay of GFP with calnexin.

These results

confirm that the information in the Bax tail is sufficient for targeting a cytosolic
protein to the mitochondria. Further, this mitochondrial-targeting signal can be
switched to an ER-targeting signal by increasing the overall hydrophobicity of the
tail.
I then established the degree of membrane targeting and insertion of
these constructs biochemically.

The GFP-taii constructs were transfected into

MEF (bax-/bak-) cells, and the cells were fractionated into lysate, cytosol, and
membrane portions. The wild-type, 3xL, and 6xL tails all result in constitutive
membrane targeting (Figure 13A).

Moreover, the membrane-associated

constructs were embedded in the membrane as assessed by resistance to
extraction by sodium carbonate (Figure 13B). This reiterates the finding that the
Bax tail contains all the information needed for the targeting and anchoring into
membrane. My results contrast with those of Vallette's group, who reported that
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the tail of Bax alone cannot target a cytosolic protein to membrane

Cartron PF, 2003.

The Bax tail used by that group was three residues shorter than the tail I have
fused to GFP in my study. I therefore generated a GFP-fused construct with the
exact portion of the Bax tail (residues 169-192) used in the previous studies.
This construct localized to mitochondria as assessed by fluorescence microscopy
(data not shown). In addition, the shortened tail was predominantly membrane
associated (Figure 13C), although a slight increase in cytosolic localization was
observed in comparison to the longer Bax tail in Figure 12A.
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FIGURE 12.
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GFP
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Figure 12. The Bax carboxy-terminus constitutes a mitochondrial-targeting
signal that can be switched to an ER-targeting signal by increasing the
overall hydrophobicity. (A) Site-directed mutagenesis was used to introduce
hydrophobic residues within the Bax tail. The tails alone (residues 166-192) were
fused to the C-terminal end of GFP. The tail sequences of wild-type Bax and the
Bax mutants are shown. The mutated residues are shown in red. (B) The GFPBax tail constructs were transfected into mouse embryonic fibroblasts lacking
Bax and Bak (MEF bax-/bak-). Confocal microscopy was then used to visualize
the localization of these constructs. An anti-Tom20 antibody and an anti-calnexin
antibody were used as a mitochondrial and ER markers, respectively.
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FIGURE 13.
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I LDH

Figure 13.

The signals in the wild-type and mutated Bax tails result in

membrane targeting and insertion of GFP. (A) The GFP-Sax tail constructs
were transfected into MEF (bax-/bak-) cells as in Figure 12. Subcellular
fractionation was used to isolate lysate, membrane, and cytosol fractions from
these cells. Western analysis was then used to analyze the localization of the
Sax tail constructs within these fractions. Tom20 and lactate dehydrogenase
(LDH) were used as a membrane marker and cytosolic marker, respectively. Llysate, M-membrane, C-cytosol. (B) Membrane fractions from (A) were
treated with 0.1 M Na2C03 (pH 11.5) and separated into pelletable and
supernatant fractions to test for stable membrane insertion. Appearance of the
construct in the pellet fraction indicates stable membrane insertion. Tom20
(membrane inserted) and cytochrome c (soluble) were used as controls. Attattached, Ins-inserted. (C) A shorter version of the wild-type Sax tail containing
residues 169-192, previously examined by Cartron et ai, was tested for its ability
to target a passenger protein to membrane fractions. Subcellular fractionation
and Western analysis were used as in (A).
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The targeting signal in the Bax tail does not play the primary
mitochondrial-addressing role in full-length Bax. Having confirmed that the
Bax tail can specifically target a cytosolic passenger protein to the mitochondria, I
tested this targeting function within the context of full-length Bax. GFP was fused
to the N-terminus of full-length Bax (Figure 14A), and the localization of this
construct was assessed using confocal microscopy.

Previous studies have

shown that fused GFP has no effect on the function of Bax Schinzel A, 2004; Nechushtan A,
1999; Wolter KG, 1997.

Under normal conditions, Bax exhibits a diffuse pattern in the

cytosol (Figure 14B).

Using ultraviolet light (UV) treatment as an apoptotic

inducer, Bax then translocated to the mitochondria. This is shown by the colocalization with the mitochondrial marker Tom20. The same 3xL and 6xL tail
mutations depicted in Figure 12A were then introduced into the full-length Bax
construct to determine if this could shift targeting of Bax from the mitochondria to
the ER (Figure 14A).

As expected, the 3xL mutant resulted in mitochondrial

targeting (Figure 14B). Surprisingly, the 6xL mutant also displayed mitochondrial
targeting, in contrast to the ER-targeting exhibited with the 6xL tail fused to GFP
as depicted in Figure 12B.

Because Bax6xL localized to the mitochondria

despite the ER-targeting signal within the tail, this suggests that the targeting of
full-length Bax does not depend on the information within the tail.
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FIGURE 14.
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overlay

Figure 14. Increasing the hydrophobicity of the Bax signal/anchor in the
context of

full~length

Bax does not alter Bax mitochondrial targeting. (A)

Mutations increasing the hydrophobicity of the Bax signal/anchor, corresponding
to those depicted in Figures 12 and 13, were introduced into a full-length Bax
construct.

GFP was fused to the amino-terminus of this construct. The tail

sequences of wild-type Bax and the Bax mutants are shown. The mutated
residues are shown in red. (B) The GFP-fused Bax constructs were transfected
into MEF (bax-/bak-) cells. Wild-type transfected cells were subjected to UV
treatment as described in materials and methods. Confocal microscopy was then
used to visualize the localization of these constructs. An anti-Tom20 antibody
was used as a mitochondrial marker.
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Deletion of the N-terminal a-helix1 of Sax disrupts mitochondrial
targeting and results in constitutive ER-targeting.

Vallette's group has

identified a potential mitochondrial-addressing signal within the N-terminal
helix1 of Bax

Cartron PF, 2003; Cartron PF, 2005; Belio! G, 2007.

Q-

This finding is in accordance

with my results that indicate that the Bax C-terminal tail is not the primary
addressing signal for Bax mitochondrial targeting. Thus, I wanted to

inv~stigate

the requirement of the Bax N-terminal domain for mitochondrial-targeting. I also
wanted to determine if the Bax tail could control Bax targeting in the absence of
the N-terminus.

I therefore deleted the entire N-terminus (6.N) containing

Q-

helix1 (residues 1-37) from wild-type Bax, as well as the 3xL and 6xL Bax tail
mutants (Figure 15A).

Localization of the GFP-fused Bax6.N constructs was

visualized in MEF (bax-/bak-) cells by confocal microscopy. As shown in Figure
15B, deletion of the N-terminal domain of Bax inhibits mitochondrial targeting and
results in predominantly ER targeting regardless of the signal within the tail. This
indicates that the N-terminal domain is required for correct mitochondrial
targeting, and that the Bax tail does not function as a targeting signal even in the
absence of the N-terminal domain.
I also determined the degree of membrane targeting and insertion of these
constructs biochemically. Each Bax6.N construct was transfected into MEF (bax/bak-) cells. The transfected cells were then fractionated into lysate, membrane,
and cytosol fractions. Deletion of the N-terminus of Bax wild-type, 3xL, and 6xL
results in constitutive membrane targeting of each construct (Figure 16A).
Moreover, each of these Bax6.N constructs is inserted within the membrane, as
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assessed by alkaline resistance (Figure 16B).

These results suggest that

deletion of the N-terminal domain disrupts the regulation of Bax that keeps it in
an inactive state within the cytosol.
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FIGURE 15.
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Figure 15. Deletion of the N-terminal a-helix1 of Bax results in a shift from
mitochondrial targeting to ER-targeting of Bax. (A) The amino-terminal

residues 1-37, including a-helix1, were deleted from the full-length wild-type, 3xL,
and 6xL Sax constructs. These proteins were expressed as GFP-fusion proteins
where GFP was fused to the N-terminus of each Sax construct. (B) The GFPfused SaxflN constructs were transfected into MEF (bax-/bak-) cells. Confocal
microscopy was then used to visualize the localization of these constructs. An
anti-Tom20 antibody and an anti-calnexin antibody were used as a mitochondrial
and ER marker, respectively.
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FIGURE 16.
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Cyt c

l

Figure 16. Deletion of the N-terminal a-helix1 of Bax results in constitutive
membrane targeting and insertion of full-length Bax. (A) The GFP-fused, full-

length BaxLlN constructs used in Figure 15 were tested. These constructs were
transfected into MEF (bax-/bak-). Subcellular fractionation was performed in
order to obtain lysate, membrane, and cytosol fractions. Localization of the Bax
constructs within these fractions was determined using Western analysis. Llysate, M-membrane, C-cytosol. (B) Membrane fractions from the MEF (bax/bak-) cells from (A) were treated with 0.1 M Na2C03 (pH 11.5) to observe
insertion properties of the Bax mutant constructs as described in Figure 13B.
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The Bax tail plays a role in regulating the membrane targeting of Bax
and the change into an open/active conformation of Bax.

Some studies

have indicated that the Bax tail functions as a regulator of Bax activation
2000; Arokium H, 2004.

Suzuki M,

As shown in Figure 14B, the 3xL and 6xL full-length Bax

mutants constitutively target to the mitochondria in the absence of an apoptotic
inducer.

Subcellular fractionation of 3xL and 6xL transfected cells displays a

constitutive membrane distribution of these mutants in both MEF (bax-/bak-) and
Hela cells (Figure 17A), in agreement with the confocal microscopy results. For
reasons that are not clear, somewhat more cytosolic Bax is observed in Hela
cells than in MEF cells.

Alkaline extraction shows that the 3xL and 6xL Bax

mutants are integrated into the membrane (Figure 17B). Conversely, wild-type
Bax is found predominantly in the cytosolic fraction (Figure 17A). These results
indicate that the mutations made within the tail disrupt a negative regulatory
effect that the tail has on Bax targeting.
To further investigate this effect, I therefore assessed the conformational
state of these Bax constructs. Previous results have demonstrated that Bax is in
a closed conformation when inactive, and when activated Bax changes into a
more open conformation, exposing a targeting signal. I wanted to determine if
the 3xL and 6xL mutations result in an open/active conformation of Bax, thereby
allowing for constitutive targeting. GFP-fused full-length wild-type, 3xL, and 6xL
Bax were transfected into MEF (bax-/bak-) cells.

A Bax antibody (6a7) that

specifically recognizes Bax in the open/active conformation was used to evaluate
the conformation of these constructs

Hsu YT, 1998; Hsu YT, 1997; Yethon JA, 2003
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confirmed, by confocal microscopy, that wild-type Sax is not recognized by the
6a7 antibody unless it is treated with UV (Figure 18A). Conversely, the 3xL and
6xL Sax mutants are in an open/active conformation in the absence of UV
treatment, as probed by staining with the 6a7 antibody. I then tested whether
this conformational change is a stable property induced by these mutations, or is
a result of membrane binding. Cytosol and membrane fractions were prepared
from transfected cells and immunoprecipitated with the 6a7 antibody.

The

immunoprecipitates were then analyzed by immunoblotting to GFP. Although the
3xL and 6xL mutants are predominantly in the membrane fraction, a small
amount of these proteins are found within the cytosol and can be measured
using this method.

Wild-type Sax does not immunoprecipitate with the 6a7

antibody and is found in the non-binding fraction as expected (Figure 18S). 3xL
and 6xL solubilized from the membrane fractions are immunoprecipitated with
6a7, in agreement with the confocal microscopy results.
immunoprecipitated from the cytosolic fraction.

Cytosolic 6xL is

This illustrates that the 6xL

mutation leads to the conformational activation of Sax directly and independently
of membrane integration.

In contrast, the cytosolic 3xL mutant was not 6a7

reactive. This may indicate that the activation of Sax by the 3xL mutation is more
transient than that induced by 6xL.
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FIGURE 17.
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Figure 17.

Mutations that increase the hydrophobicity of the 8ax

tail/anchor result in constitutive membrane targeting and insertion of fulllength 8ax (A) The GFP-fused, full-length Bax constructs used in Figure 14
were tested. These constructs were transfected into MEF (bax-/bak-) cells and
Hela cells. Subcellular fractionation was performed in order to obtain lysate,
membrane, and cytosol fractions. Localization of the Bax constructs within these
fractions was determined using Western analysis. L-Iysate, M-membrane, Ccytosol. (8) Membrane fractions from the MEF (bax-/bak-) cells from (A) were
treated with 0.1 M Na 2 C0 3 (pH 11.5) to observe insertion properties of the Bax
mutant constructs as described in Figure 13B.
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GFP

Figure 18.

The mutations made in the Bax tail result in an active

conformation of Bax. (A) The GFP-fused Bax constructs were transfected into

MEF (bax-/bak-) cells.

Wild-type transfected cells were subjected to UV

treatment as described in materials and methods. Bax (6a?) antibody was used
to specifically detect Bax in an active conformation. Confocal microscopy was
used to visualize binding of the 6a? antibody. (B) Immunoprecipitation (IP) with
the Bax (6a?) antibody was used to pull-down GFP-fused WT, 3xL, or 6xL Bax
that was in the active conformation. The IPs were performed on either cytosolic
or membrane subcellular fractions. Probing for WT in the cytosol was used as a
negative control. The IP samples, as well as the non-binding fractions, were then
analyzed using Western analysis and a GFP-specific antibody to detect the Bax
constructs.
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Deletion of the Bax tail results in an open/active conformation of
Bax, yet Bax cannot target to the mitochondria without the tail. Studies by
various groups have produced contradictory findings on the requirement of the
Bax tail for Bax targeting and activity. My results indicate that the Bax tail is not
the primary targeting signal for mitochondrial targeting, yet the tail plays an
important role in the regulation of Bax conformational change and targeting.
Therefore, I deleted the Bax tail to test whether this domain is dispensible for Bax
activation and targeting.

The deletion mutant

(Bax~C)

was generated by

removing residues 169-192, which includes a-helix9 and its flanking residues,
from GFP-fused full-length Bax (Figure 19A).

To determine the effect of this

deletion on the conformational state of Bax, I used the Bax 6a7 antibody specific
for the active conformation of Bax. BaxL1C was transfected into MEF (bax-/bak-)
cells, and confocal microscopy was used to analyze Bax 6a7 binding with or
without UV treatment.

The deletion of the Bax tail resulted in an open/active

conformation of Bax independent of an apoptotic inducer as measured by 6a7
reactivity (Figure 19B). This result supports my findings with the 3xL and 6xL tail
mutants that the tail is an important negative regulator of Bax activation,
specifically by maintaining Bax in a closed/inactive conformational state.
Because BaxL1C is in an open/active conformation, it would be expected that
BaxL1C would constitutively target to the mitochondria, as seen with 3xL and 6xL.
Therefore, BaxL1C was transfected into MEF (bax-/bak-) cells, and localization of
this construct was assessed by confocal fluorescence with or without UV
treatment. Surprisingly, despite the fact that

66

Bax~C

is in an active conformation,

this construct remains predominantly in the cytosol even upon apoptotic induction
by UV treatment (Figure 20A).

Subcellular fractionation of BaxLiC-transfected

Hela cells reinforces these results.

As previously observed, wild-type Bax

becomes membrane localized after UV treatment, yet BaxLiC remains in the
cytosol (Figure 20B).

Therefore, while the Bax tail does not dominate the

organelle-specific targeting, this sequence is essential for membrane integration
of Bax.
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FIGURE 19.
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Figure 19. Deletion of the Bax tail results in an active conformation of Bax.
(A) A tail-deleted form of Sax (~C) was generated by deletion of residues 169-

192. The ~C mutant was fused to the C-terminus of GFP. (B) The GFP-fused
Sax~C

construct was transfected into MEF (bax-/bak-) cells. The Sax (6a7)

antibody was used to specifically detect Sax in an active conformation. Confocal
microscopy was used to visualize binding of the 6a7 antibody in the absence or
presence of UV treatment.
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FIGURE 20.
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Figure 20.

Deletion of the Bax tail results in a cytosolic distribution

independent of apoptotic stimulus. (A) The GFP-fused

Bax~C

construct was

transfected into MEF (bax-/bak-) cells. Confocal microscopy was then used to
visualize the localization of this construct. An anti-Tom20 antibody was used as a
mitochondrial marker. (B) BaxWT and

Bax~C

were transfected into Hela cells

and were either treated or not treated with UV light. Subcellular fractionation was
performed to obtain lysate, membrane, and cytosol fractions. Localization of the
Bax constructs within these fractions was determined using Western analysis.
L-Iysate, M-membrane, C-cytosol.
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FIGURE 21.
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The constitutively-targeted

3xL and 6xL Bax mutants exhibit

enhanced apoptotic-inducing ability in comparison to wild-type and AC
Bax.

Bax 3xL, 6xL, and I1C mutants are all in an open/active conformation.

However, while 3xL and 6xL are constitutively mitochondrial-targeted, Baxl1C is
constitutively cytosolic. This prompted us to evaluate the subsequent apoptoticinducing ability of these Sax mutants in the absence of an apoptotic stimulus in
Hela cells.

These cells produce more robust apoptotic signals than the MEF

cells used in the experiments depicted above. Sax wild-type, 3xL, 6xL, and I1C
were transfected into Hela cells along with empty vector as a negative control,
and apoptosis was measured without addition of an apoptotic inducer.

PARP

cleavage and caspase-3 cleavage were used to measure apoptosis. As shown
in Figure 21, wild-type Sax and Baxl1C do not stimulate apoptosis and are
comparable to vector alone. Conversely, 3xL and 6xL show clear induction of
apoptosis in the absence of an external apoptotic stimulus, as measured by
PARP and caspase-3 cleavage.
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Figure 21. In the absence of apoptotic stimulus, the constitutively-targeted
3xL and 6xL mutants of Bax exhibit enhanced apoptosis in comparison to
BaxWT and BaxflC. GFP-fused Sax constructs were transfected into Hela cells

for 24 hours. Lysates from these cells were then subjected to Western analysis.
An antibody that specifically recognizes cleaved PARP and an antibody that
specifically recognizes cleaved caspase-3 were used as a measure of apoptosis.
LDH was used as a loading control. EV-empty vector
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Inhibiting insertion of the Bax tail disrupts Bax
targeting.

mitochondrial~

My results have revealed that the Bax tail does not play the

addressing role in Bax mitochondrial targeting. However, I have shown that the
tail is indispensable for Bax targeting.

This led us to investigate whether the

membrane-insertion property of the Bax tail is important for Bax mitochondrial
translocation.

Selected residues within the Bax hydrophobic transmembrane

domain of the tail were replaced with charged residues in order to inhibit insertion
of the tail into the membrane (Figure 22A).

Residues G179 and T186 were

chosen due to their location in the middle and end of the transmembrane
segment, respectively.

S184 was chosen because previous studies have

identified this residue as having effects on Bax mitochondrial targeting
1999; Gardai SJ, 2004; Xin M, 2005.

Nechushtan A,

V180 and L 185 were chosen in order to replace

hydrophobic residues of the transmembrane sequence rather than polar
residues. Initially, the tails in the context of GFP as a passenger protein were
assessed by microscopy to confirm that these sequence changes disrupt the
membrane insertion of the tail sequence (Figure 22B, first column). GFP was
fused to the N-terminus of each of the mutant tails. The GFP-taii constructs were
transfected into MEF (bax-/bak-) cells, and localization was visualized using
confocal microscopy. Introducing a single charged residue at serine 184 (S184K,
S1840, S184E) or substituting two charged residues for hydrophobic residues
(V180K,L 185K) resulted in a diffuse, cytosolic distribution. This contrasts sharply
with the distinct mitochondrial targeting of GFP fused to the wild-type and 3xL
sequence or the endoplasmic reticulum targeting of the 6xL sequence (Figure
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12).

However, T186K and G179K tails only partially inhibited the targeting of

GFP to mitochondria. Although a portion of these latter constructs is localized to
the mitochondria, a significant amount is diffuse throughout the cell.
The effects of these same mutations were then investigated in the context
of full-length Bax.
mutants.

GFP was fused to the N-terminus of the full-length Bax

These constructs were transfected into MEF (bax-/bak-) cells.

Transfected cells were then subjected to analysis using confocal microscopy and
subcellular fractionation. The introduction of charged residues within the Bax tail
resulted in an open/active conformation of Bax, as detected by 6a7 reactivity
(Figure 22B). However, even in the active conformation, Bax is not able to target
to the mitochondria with a mutated tail that cannot insert.

All of the mutants

display a cytosolic distribution (Figures 22B and 22C). This is in contrast to Bax
3xL and 6xL mutants that are in the active conformation, yet constitutively target
to the mitochondria (Figures 14 and 17, Table 2). These results indicate that
inhibiting the ability of the tail sequence to insert into membranes disrupts
mitochondrial targeting of Bax.

76

FIGURE 22.
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Figure 22.

Inhibiting insertion of the Bax tail by introducing charged

residues disrupts Bax mitochondrial-targeting. (A) Site-directed mutagenesis
was used to introduce charged residues within the Bax tail. These mutations
were made in both GFP-tagged full-length Bax as well as GFP fused to the tails
alone (residues 166-192). The tail sequences of wild-type Bax and the 8ax
mutants are shown. The mutated residues are shown in red. (B) The GFP-taii
and GFP-Bax (full-length) constructs were transfected into MEF (bax-/bak-) cells.
Confocal microscopy was then used to visualize the localization of these
constructs. An anti-Tom20 antibody and an anti-calnexin antibody were used as
a mitochondrial and ER marker, respectively. 8ax 6a7 antibody was used to
detect the open/active conformation of full-length 8ax constructs. (C) The GFPfused, full-length 8ax mutants used in (8) were tested. These constructs were
transfected into MEF (bax-/bak-) cells. Subcellular fractionation was performed in
order to obtain lysate, membrane, and cytosol fractions. Localization of the 8ax
constructs within these fractions was determined using Western analysis. Llysate, M-membrane, C-cytosol.
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TABLE 4.

Table 4 Summary of conformation and localization of Bax constructs
Bax

6a7 Reactivity

Construct

Mitochondrial

Cytosolic

localization

localization

X

WT

3xL

x

X

6xL

X

X

AC

X

X

T186K

X

X

G179K

X

X

5184K

X

X

5184D

X

X

5184E

X

X

V180K, L185K

X

X

wr

Shown are a list of the names given to Bax
and the Bax mutants. An open/active conformation is
indicated by 6a7 reactivity. Mitochondrial or cytosolic localization is also indicated.
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CHAPTER IV
DISCUSSION

In these studies, I first show that the carboxy-terminal tail of Bax can serve
as a bona-fide mitochondrial-targeting signal/anchor.

Surprisingly, despite this

property I demonstrate that the Sax tail does not play the primary role in
addressing of full-length Bax to the mitochondria. However, I show that the Bax
tail does play an important negative regulatory role in Bax activation of targeting.
Deletion of the Sax tail results in an open/active conformation, yet Sax cannot
localize to the mitochondria without the Sax tail. This indicates a requirement of
the Sax tail for Sax mitochondrial translocation. Sy making mutations within the
Sax tail that inhibit insertion of this domain, I illustrate that the membrane
insertion of the Bax tail is crucial for Sax mitochondrial targeting.
Studies on Sax have yielded conflicting results as to whether the Sax tail
functions as a targeting signal that is necessary for Sax mitochondrial
translocation. There have been reports that the Bax tail cannot target a fused
cytosolic passenger protein to the mitochondrial membrane, suggesting that the
Sax tail does not contain a mitochondrial-targeting signal
1999.

Cartron PF, 2003; Nechushtan A,

Vallette's group has also presented findings in which the deletion of the Sax

tail has no effect on mitochondrial targeting or apoptotic inducing ability in
comparison

to

wild-type

Sax,

indicating
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that

the

Sax

tail

is

dispensible for targeting and Bax activation
1999.

Cartran PF, 2005; Cartran PF, 2003; Tremblais K,

In addition, they have identified a potential targeting signal within the N-

terminal a-helix1 of Bax that directly interacts with the MOM receptor Tom22.
On the other hand, several other groups have presented results that
indicate a mitochondrial-targeting function of the Bax tail. Studies have shown
that the Bax tail itself contains sufficient mitochondrial-targeting and anchoring
information when fused to a cytosolic passenger protein

Gaping IS, 1998; Schinzel A 2004.

Deletion of the Bax tail can prevent targeting of full-length Bax to the
mitochondria as well as inhibit the apoptotic inducing ability of Bax
Wolter KG, 1997; Nechushtan A, 1999.

Schinzel A, 2004;

Nechushtan et al showed that even deletion of the

last 5 amino acids from the Bax tail can inhibit targeting. In the same study, they
demonstrated that various point mutations at residue S184 in the Bax tail either
increased or inhibited Bax mitochondrial targeting, further indicating an important
targeting role of the Bax tail.

These localization and functional studies have

established that the Bax carboxy-terminus serves a role identical to that of
homologous sequences in other "tail-anchored" proteins, in which the carboxy
terminus serves as both the addressing signal and membrane anchor

Wolter KG,

1997; Gaping IS, 1998; Hsu YT, 1998; Nguyen M, 1993

In my hands, it is clear that the Bax tail itself can serve as a mitochondrialtargeting signal and can direct a cytosolic passenger protein specifically to the
mitochondria. Moreover, the behavior of the 6xL mutation demonstrates that the
tail obeys the sequence rules that determine whether tail-anchors direct proteins
to the mitochondria versus the endoplasmic reticulum. The varying lengths of the
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Bax tail used in previous studies may account for the differences in results.
Vallette's group used residues 169-192. In contrast, I used residues 166-192 of
the Bax tail, which contains the entire transmembrane domain in addition to the
N-terminal and C-terminal flanking residues. Studies of targeting requirements
for tail-anchored proteins have demonstrated that the residues flanking the
hydrophobic portion of the membrane anchor are essential for targeting
1998; Kaufmann T, 2003; Masaki R, 2003; Kim PK, 1997.

Isenmann 8,

Shorter portions of the Bax tail may not

contain all of the essential residues for correct mitochondrial targeting, resulting
in cytosolic localization.

Using a shorter Bax tail segment (residues 169-192)

that was used by Vallette's group, I show that although this shorter version can
still target to the mitochondria to some extent, the efficiency is lower than the
longer version (Figure 13C).
However, my results are in agreement with the notion of the mitochondrialtargeting signal of Bax residing in the N-terminal a-helix1 and not in the Bax tail
Cartron PF, 2003.

I demonstrate that replacing the C-terminal tail of Bax with an ER-

targeting signal (6xL) has no effect on targeting of full-length Bax. This indicates
that another targeting-signal exists in the structure of Bax that overrides the
targeting signal within the tail, refuting the idea that the tail is the primary
targeting signal within Bax. In accordance with this, when I deleted the Bax Nterminal domain including a-helix1, mitochondrial-targeting of Bax was abolished.
Instead, BaxflN localized predominantly to the ER. Additionally, translocation to
the ER was observed independently of the targeting signal within the tail. This is
consistent with the results of Vallette's group that indicate that the primary
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mitochondrial-targeting signal is within the N-terminal a-helix1 domain. It is not
clear why the N-terminal deleted form of Sax targets to the ER. Localization of
wild-type Sax to the ER is not widely studied at this point. Therefore, little is
known about the mechanism of Sax targeting to this organelle. It is possible that
there is another targeting signal within the Sax structure that allows for targeting
to the ER.
While the Sax tail does not serve as a targeting sequence, I find that it is
absolutely required for Sax localization to the mitochondria.

What then is its

function? My results suggest that the Sax tail tethers Sax to the mitochondrial
membrane subsequent to or in conjunction with a targeting interaction mediated
by sequences elsewhere in the protein. I come to this conclusion based on my
observation that disrupting the ability of the tail sequence to insert into
membranes blocks Sax mitochondrial localization.

This finding provides a

possible explanation for the necessity of the Sax tail for targeting, and is
consistent with the results obtained when the Sax tail is deleted and
mitochondrial targeting is inhibited.

Interestingly, previous studies have shown

that Sax mitochondrial translocation can be inhibited by phosphorylation of the
tail residue 8184

Gardai

SJ,

2004;

Xin

M,

2005

My results suggest that this

phoshorylation prevents the required membrane insertion of the tail, thereby
inhibiting Sax targeting. My data using the phosporylation-mimicking residues D
and E at residue 8184 are consistent with this notion. I cannot rule out that the
introduction of charged residues within the tail does not have additional effects
on the Sax protein. The inhibition of mitochondrial targeting that is observed with
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these tail mutants could also be due, in part, to disruption or promotion of Bax
interaction with other proteins.

It is also unclear why Vallette's group has

described the Bax tail as being dispensible for Bax mitochondrial-targeting.
Expression level differences or cell-type differences could result in suitable
conditions for stable association of the tail-deleted form of Bax with the
mitochondria, accounting for these discrepancies.
The Bax tail also appears to function as a negative regulator of Bax
activation

Suzuki M, 2000; Arokium H, 2004.

The C-terminal tail of Bax is tucked into a

hydrophobic pocket in the structure of Bax, covering the BH3 domain and ahelices 5 and 6. The tail is retained in the pocket by hydrophobic interactions
and hydrogen bonding

Suzuki M, 2000.

Replacement of the Bax tail with the C-

terminal tail of either BcI-2 or BcI-xL results in constitutive mitochondrial targeting
of Bax

Goping IS, 1998; Suzuki M, 2000; Tremblais K, 1999.

Whereas the conserved sequence of

the Bax tail allows for a tight fit into the hydrophobic pocket, the imperfect fit of
the alternative tails into the hydrophobic groove allows for an open/active
conformation of Bax. This would result in the constitutive exposure of the tail
sequence and the activation of Bax.

My results have demonstrated a

comparable phenomenon, where mutations within the Bax tail result in an
open/active conformation of Bax, constitutive mitochondrial targeting, and
enhanced apoptotic-inducing ability.

Moreover, mutation of six residues within

the tail, rather than three, had a greater effect on Bax conformation, reiterating
the idea that increased disruption of the interactions between the tail and the
hydrophobic groove results in dissocation of the Bax tail. The complete deletion
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of the tail also results in an open conformation of Sax, illustrating that the specific
positioning of the tail within the hydrophobic pocket is important in maintaining
Bax in a closed/inactive conformation. This negative regulatory role of the Bax
tail is comparable to that of the ART (apoptotic regulation of targeting) domain in
the N-terminal portion of Bax Goping IS, 1998; Cartron PF, 2005; Cartron PF, 2003.
Taken together, my findings have presented possible explanations for the
conflicting results describing the function of the Bax tail.

My results support

previous findings that the Bax tail serves as a negative regulator of the initial
conformational change that leads to Bax mitochondrial translocation. While my
data contradict the notion that the Bax tail serves as the primary targeting signal
for mitochondrial targeting, I suggest an important anchoring/tethering role of the
Bax tail that is required for mitochondrial targeting of Bax. I propose a model
where after the initial addressing of Sax to the MOM, the Bax tail functions to
stabilize Bax at the membrane (Figure 23). This would then allow for complete
integration of Bax into the membrane where helices 5 and 6 can be inserted.
Consistent with this model, Andrews and colleagues also suggest a stepwise
process of transient to stable interaction of Bax with the membrane
Leber B, 2007.

Yethon JA, 2003;

Further studies will be needed to elucidate greater detail of this

insertion process.
It is well accepted that translocation of Bax to the mitochondria is essential
for Bax-induced apoptosis.

The numerous studies on Bax have uncovered

various mechanisms involved in Bax activation and mitochondrial translocation. I
believe that Bax activation and translocation are achieved through a stepwise
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process that consists of these various mechanisms that have been identified.
Bax is retained in an inactive state in the cytosol due to a specific conformation of
Bax. The N-terminal ART sequence and the carboxy-terminal tail of Bax serve to
keep Bax in an inactive/closed conformation.

By sitting in the hydrophobic

groove, the Bax tail also functions to cover the Bax BH3 domain that can interact
with activating proteins such as tBid.

Inhibitory proteins, such as 14-3-3 and

Ku70, can also bind to Bax and maintain Bax in an inactive conformation.
Interactions with the inhibitory proteins must be disrupted and Bax must
undergo a conformational change before it can translocate to the mitochondrial
outer membrane (MOM). It is unclear what triggers this conformational change
of Bax, though addition of cytosolic extract stimulates translocation of
recombinant Bax.

Therefore, it is likely that activating proteins are involved.

These proteins may induce a conformational change by competing with the Bax
tail for the BH3 domain in the hydrophobic pocket. The best described example
of a Bax activating protein is the BcI-2 BH3-only protein, Bid. The truncated form
of Bid, tBid, induces Bax conformational change and mitochondrial translocation.
tBid has been shown to interact with the BH3 domain of Sax, hence this
interaction could facilitate release of the Bax tail and the subsequent activating
conformational change. In addition, other factors may serve as indirect activators
by blocking the inhibitory actions of the inhibitory proteins. This is exemplified by
the action of the BH3-only proteins that block the Bax-inhibitory proteins BcI-2
and Bcl-xL.
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I believe that the conformational change of Bax allows for exposure of a
mitochondrial

signal,

possibly

a-helix1

of the

Bax

N-terminus.

This

mitochondrial-targeting signal interacts loosely with a factor at the surface of the
mitochondria and does not insert into the MOM.

The interaction of the Bax

mitochondrial-targeting signal with the mitochondria is transient until the Bax Cterminal tail inserts into the membrane. Insertion of the Bax tail is essential for
tethering of Bax to the mitochondrial membrane. The insertion of the Bax tail
then stabilizes Bax for complete integration of Bax a-helices 5 and 6 into the
MOM. Once the Bax tail is inserted, I believe that the subsequent integration of
a-helices 5 and 6 occurs rapidly.
This proposes a complex model that involves a stepwise process of Bax
activation. This sequential activation allows for a tight regulation of Bax due to
the number of steps that are required for complete activation. Tight control is
vital to keep Bax from aberrantly being activated, since Bax is such a potent
stimulus of cell death.

Future studies need to focus on verifying each step.

However, it is difficult to isolate intermediate steps in order to show it is in a
stepwise fashion. Identifying all of the steps of Bax activation will provide more
pOints of intervention in the context of potential therapeutic targets.
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FIGURE 23.
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Figure 23.

Model of Bax targeting to the mitochondria. Sax is found in a

closed/inactive state in the cytosol.

The correct orientation of the tail in the

hydrophobic pocket keeps Sax in a closed/inactive conformation. 1) An apoptotic
trigger induces a conformational change into an open conformation of Sax,
thereby exposing a mitochondrial-addressing signal. 2) The exposed addressing
signal interacts with the mitochondrial membrane in a loose fashion whereby Sax
can attach and detach from the membrane. 3) The Sax tail must insert into the
MOM, tethering Sax to the membrane and 4) allowing for complete integration of
Bax into the bilayer.
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CHAPTER V
RELATED PROJECT:
A PEPTIDE DERIVED FROM A MITOCHONDRIAL TAIL-ANCHOR SHOWS
AN INCREASED PROPENSITY FOR HELIX FORMATION AS COMPARED
TO A PEPTIDE DERIVED FROM AN ER-DIRECTED SEQUENCE

Introduction

Tail-anchored proteins consist of an N-terminal cytosolic globular domain
that is tethered to an intracellular membrane by a C-terminal hydrophobic
transmembrane domain , or tail-anchor
Borgese N, 2003.

Wattenberg BW, 2001; Borgese N, 2003; Habib SJ, 2003;

The C-terminal transmembrane domain serves as the addressing

signal as well as the anchor that tethers the protein to the correct membrane
Wattenberg BW, 2001; Habib SJ, 2003; Borgese N, 2003.

Because the C-terminal sequence is the

final portion of the protein to exit the ribosome during translation, targeting to the
destination membrane is post-translational.

Tail-anchored proteins localize

initially to the endoplasmic reticulum or the mitochondria, and to a lesser extent
at peroxisomal membranes

Borgese N, 2003.

The targeting signal within the C-

terminal tail that differentiates between membranes does not consist of specific
amino acid sequences.

Instead, distinctive structural characteristics of the tail

allow for differential targeting (Table 2).

These characteristics include

hydrophobicity, polarity, charged flanking-residues, and spacing of residues
Borgese N, 2001; Horie C, 2002; Isenmann S, 1998; Habib SJ, 2003
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ER-targeted tail-anchored

proteins contain relatively hydrophobic transmembrane sequences. Alternatively,
mitochondrial-targeted

tail-anchored

proteins

contain

less

hydrophobic

transmembrane domains due to the presence of polar residues or due to
containing shorter transmembrane segments.

The mitochondrial-targeting tail

anchors also contain positively-charged residues that flank the transmembrane
sequence. A relevant example of these properties can be described with two
splice isoforms, A and B, of the tail-anchored protein VAMP1

Isenmann S, 1998.

VAMP1A targets specifically to the ER. The tail anchor of VAMP1 B differs from
the tail anchor of VAMP1A only by shortening of the hydrophobic transmembrane
domain and the addition of positively charged residues at the end of the tailanchor sequence.

These slight changes allow for targeting of VAMP1 B

specifically to the mitochondria. Although these general structural characteristics
have been established, the mechanism by which these differing structures
selectively target to destination membranes is poorly understood. To shed more
light on the differences in biophysical properties of mitochondrial- versus ERtargeted tail anchors, I investigated differences in secondary structure formation
of representative artificial tail-anchor sequences.

Materials and Methods
Circular dichroism of tail-anchor peptides

The following synthetic peptides (Invitrogen) were examined by circular
dichroism:

MOA-tail

(KSGSGSRIIGFSTSVTALGFVLYRYRLLPRS)

(KSGSGSRLLLLLLLLLLLLLLLLRYRLLPRS).
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Differing

and

L16

concentrations

of

trifluoroethanol (TFE) or dodecylphosphocholine (OPC; Avanti Polar Lipids) in
10mM phosphate buffer, or 4mM SOS in 5mM Tris pH 7.6 were used to solubilize
the peptides.

Peptide concentrations were determined using absorbance

readings at a wavelength of 220.

Concentrations corresponding to an

absorbance reading of 0.7-0.8 were found to be optimal for CO readings.
Spectra were collected on a Jasco J-800 spectropolarimeter equipped with a
thermoeclectric temperature control unit. Parameters for the CD analysis are as
follows: temperature-20°C, sensitivity-standard (100mdeg), start-260nm,
end-178nm, data pitch-0.2nm,

scan mode-continuous, scan speed-

50nm/min, response-2s, bandwidth-1 nm, accumulation-10.

The spectra

resulting from the CD analysis were analyzed using CONTINLL software to
determine the percent of helical conformation Provencher SW, 1981.

Results and Discussion

Tail-anchors direct targeting based on distinct structural characteristics
rather than specific sequence requirements.
secondary structure,

I determined

differing

By measuring the formation of
biophysical

mitochondrial- versus an ER-targeted tail-anchor peptide.

properties

of a

The mitochondrial-

targeted tail-anchor peptide was derived using sequence from the tail-anchor of
the

mitochondrially-targeted

protein

KSGSGSRIIGFSTSVTALGFVLYRYRLLPRS.

monoamine

oxidase:

A poly-leucine sequence was

used to represent an ER-targeted tail-anchor peptide, based on the high
hydrophobicity characteristics of ER-targeted tail-anchors.

92

This poly-leucine

sequence was substituted into the tail-anchor sequence of monoamine oxidase:
KSGSGSRLLLLLLLLLLLLLLLLRYRLLPRS.

Both of these sequences were

confirmed to target to the specified membrane (Table 2). Two conditions were
used to measure the propensity of these peptides to form secondary structure.
First, I wanted to test increasing concentrations of trifluoroethanol (TFE), a
solvent that promotes helix formation. Secondly, dodecyl phosphocholine (DPC)
was used as a membrane-mimetic zwitterionic detergent.
Peptides were first dissolved in aqueous buffer containing increasing
concentrations of TFE.

Circular dichroism was used to determine secondary

structure at the various concentrations.

Figure 24A shows the delta epsilon

measurements versus wavelength for the mitochondrial tail-anchor peptide,
MOA, at the increasing TFE concentrations. The corresponding curves for the
ER-targeted tail-anchor peptide, L16 , are displayed in Figure 24B.

Both peptides

exhibit a-helical formation upon increasing concentrations of TFE. This is shown
by the characteristic spectrum indicative of a-helical secondary structure, a
maximum peak around 195nm and two minimum peaks around 209nm and
222nm. In aqueous buffer and at a lower concentration of TFE, the spectra are
indicative of random coil structure. Random coil secondary structure is depicted
by a minimum peak around 195-200nm.

In buffer containing 25% TFE, the

MOA-tail peptide appears to have more helical formation than the L16-tail peptide
(Figure 24C). This is evident from the increase in delta epsilon for the MOA-tail
peptide at 192nm, characteristic of alpha helix formation. This is also illustrated
in Figure 24D where the calculated percentage of alpha helix was graphed
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FIGURE 24.
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Figure 24.

The mitochondrially targeted MOA-tail peptide has a higher

propensity for TFE-induced a-helix formation than the ER-targeted peptide
L 16. Synthetic peptides were dissolved in aqueous buffer containing the
indicated amounts of TFE. Circular dichroism was measured as described in
Materials and Methods. (A) MOA-tail peptide was measured with 0, 10%, 25%,
40%, 50%, and 100% TFE.

Results are reported as delta epsilon. (8) L 16

peptide was measured as in panel (A). (C) The spectra for 25% TFE are shown
in greater detail for comparison of MOA-tail peptide and the L16 peptide. (0) The
percent helical content, calculated as described in Materials and Methods, is
plotted for the two peptides versus TFE concentration.
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versus TFE concentration. Both peptides reached maximum helix formation in
40% TFE.

However, while MOA-tail peptide was highly helical (76%) in 25%

TFE, L16-tail peptide was only slightly more helical (38%) than in completely
aqueous buffer. This indicates that the mitochondrial-targeted tail-anchor peptide
has a greater propensity to form helical structure in a helix-promoting solvent.
These peptides exhibited similar behavior in OPC. The MOA-tail peptide
exhibited helical formation even at the lowest concentration of 0.8mM OPC
(Figure 25A).

In contrast, the L16-tail peptide did not display helical formation

until a higher concentration of 30mM OPC was used (Figure 25B).

Percent

helical content of these peptides at the various OPC concentrations is graphed in
Figure 25C. As shown above, the MOA-tail peptide shows a higher propensity to
form a helix in increasing concentrations of OPC, in comparison to the L16-tail
peptide~ It should be noted that the concentrations of OPC were chosen in terms

of the amount of micelle that is formed. The critical micelle concentration of OPC
is 1.1 mM

Stafford RE,

1989. At 0.8mM, OPC is entirely monomeric. At 3mM, there is

more or less an even distribution of OPC in monomeric versus micelle form. At
30mM, OPC is predominantly in micelles. Therefore, while the MOA-tail peptide
exhibits a tendency to form helix in the presence of monomeric OPC, the L16-tail
peptide does not.

However, both peptides display helical formation in the

presence of micellar OPC. A summary of these data are represented in Table 3.
Comparisons of the percent helicity in the various solutions demonstrate an
increased propensity of the MOA-tail peptide to form helix compared to the L16tail peptide.
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As the data indicate, the mitochondrial-targeted tail-anchor peptide more
readily forms a-helical secondary structure in comparison to the ER-targeted tailanchor peptide.

This illustrates divergent biophysical properties that could

account for the differential targeting of these tail-anchor sequences.

In the

context of physiological tail-anchored proteins, the translocation to differential
membranes could depend partly on the helix-forming propensity of the various
tail anchors.

Future studies should expand this analysis by looking at larger

subsets of mitochondrial- versus ER-targeted tail anchors.
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FIGURE 25.
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Figure 25.

The mitochondrially targeted MOA-tail peptide has a higher

propensity for a-helix formation in the membrane mimetic OPC than the
ER-targeted peptide L 16. Synthetic peptides were dissolved in aqueous buffer
containing the indicated amounts of OPC. Circular dichroism was measured as
described in Materials and Methods. (A) MOA-tail peptide was measured with
O.3mM, 3mM, and 30mM OPC. Results are reported as delta epsilon. (8) L 16
peptide was measured as in panel (A). (C) The percent helical content,
calculated as described in Materials and Methods, is plotted for the two peptides
versus OPC concentration.
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TABLE 5.

Table 5 Summary of alpha helix content of the indicated peptides in the solutions shown
Solution

MOA-tail % helix

Lu,tail % helix

Phosphate Buffer

18

21

10% TFE

18

15

25% TFE

76

38

40% TFE

98

98

50% TFE

98

95

ope
3mM ope
30mM ope

73

18

99

51

99

99

0.8mM

Alpha helix content was calculated from the curves shown in Figs 12 and 13 as described in
Materials and Methods. The remainder of the structure was almost exclusively random coil.
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